BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Nov 03, 2008
 |  BioCentury  |  Strategy

Reaching for the summit in TB

When it comes to deals, it's the larger partner that generally gets the commercialization rights in the major markets. But to get rights to a tuberculosis compound from Summit plc for its Lilly TB Drug Discovery Initiative, Eli Lilly and Co. let Summit retain rights in the developed world. What the TB Initiative gets is a series of compounds specific to Mycobacterium tuberculosiswith a novel mechanism of action that the pharma would market in the developing world.

The public-private partnership, which Lilly formed in June 2007, announced the acquisition of its first two compounds last month: an unnamed compound from Summit, and CPZEN-45, which was donated by the non-profit Microbial Chemistry Research Foundation (MCRF).

According to Gail Cassell, VP of scientific affairs at Lilly and chair of the TB Initiative's steering committee, CPZEN-45 is much further along. It has shown efficacy against multi-drug resistant (MDR)- and extensively drug resistant (XDR)-TB in infected mice and has undergone toxicology testing. Nevertheless, she said, the compound could not be considered a clinical candidate for at least another year and a half.

Both MCRF and Summit approached Lilly when they learned of the TB Initiative.

Summit screens...

Read the full 959 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >